Gene Synthesis Market Size and Share
Gene Synthesis Market Analysis by Mordor Intelligence
The gene synthesis market size stands at USD 2.45 billion in 2025 and is forecast to reach USD 5.29 billion by 2030, advancing at a 16.64% CAGR. This rapid expansion reflects sustained breakthroughs in enzymatic oligonucleotide production, larger research budgets for precision genomics, and surging demand from biopharmaceutical companies seeking faster design-build-test cycles [1]NHGRI, “Genomic Technology Grants,” genome.gov . Growing regulatory clarity also supports the gene synthesis market, with the Biden administration’s Executive Order on AI and biotechnology outlining new federal screening rules that create common operating standards for providers. Manufacturing capacity is playing catch-up because oligonucleotide demand is rising 30% each year even as synthesis productivity improves more slowly than sequencing throughput. In parallel, 10 gene therapies gained FDA approval in 2024—twice the prior year’s figure—showing how regulatory momentum accelerates commercial orders for long, high-fidelity constructs.
Key Report Takeaways
- By synthesis method, chemical oligonucleotide synthesis held 55.45% gene synthesis market share in 2024, while gene assembly technologies are projected to expand at a 17.21% CAGR through 2030.
- By service type, antibody DNA synthesis accounted for 48.28% of the gene synthesis market size in 2024; viral gene synthesis are on track for a 17.34% CAGR to 2030.
- By application, gene and cell therapy accounted for 52.21% of the gene synthesis market size in 2024; disease-diagnosis uses are on track for a 17.37% CAGR to 2030.
- By end user, biopharmaceutical companies generated 46.23% of revenue in 2024, whereas CROs and CDMOs are poised for the fastest 17.43% CAGR as outsourcing accelerates.
- By geography, North America commanded 42.31% of the gene synthesis market size in 2024, yet Asia-Pacific is set to grow the quickest at a 17.61% CAGR over the forecast period.
Global Gene Synthesis Market Trends and Insights
Drivers Impact Analysis
Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
---|---|---|---|
Surging genomics & NGS-driven R&D pipelines | +3.2% | Global, concentrated in North America & Europe | Medium term (2-4 years) |
Expanding biopharma demand for synthetic genes | +4.1% | Global, led by North America, Asia-Pacific growth | Short term (≤ 2 years) |
Government genomics-funding initiatives | +2.8% | North America, Europe, China, India | Long term (≥ 4 years) |
Rapid drop in DNA-synthesis cost & turnaround | +3.5% | Global, manufacturing hubs in Asia-Pacific | Medium term (2-4 years) |
Emerging enzymatic DNA-synthesis platforms | +2.9% | North America & Europe development, Global adoption | Medium term (2-4 years) |
Venture-capital rush into bio-foundries & cloud labs | +1.7% | North America, Europe, selective Asia-Pacific markets | Short term (≤ 2 years) |
Source: Mordor Intelligence
Surging Genomics & NGS-Driven R&D Pipelines
More than 900 active clinical trials in North America now incorporate synthetic DNA constructs, underscoring how next-generation sequencing pushes laboratories toward higher-throughput build capabilities. CEPI has committed USD 4.7 million to automate DNA Script’s template production so vaccine developers can move from design to bench in days rather than weeks [2]CEPI, “Funding Award to DNA Script,” cepi.net . Academic progress supports the driver: University of Hawaii researchers achieved 96% editing success when using high-fidelity templates, demonstrating direct links between synthesis quality and therapeutic efficacy [3]University of Hawaii, “High-Fidelity Gene Editing Study,” hawaii.edu. NHGRI’s USD 2.2 million grant for multiplex oligo synthesis further embeds synthetic DNA as critical research infrastructure. Together, these elements enlarge sample backlogs and create premium opportunities for providers able to guarantee error-free sequences on demand.
Expanding Biopharma Demand for Synthetic Genes
Biopharmaceutical pipelines now depend on custom genes for cell therapies, mRNA vaccines, and antibody-drug conjugates. The FDA cleared five gene therapies in 2024, including the first CRISPR-edited treatment, and each approval validates commercial need for precise, viral-vector-ready inserts. GSK invested USD 35 million in Elegen to secure linear DNA that fits its mRNA vaccine portfolio. Clinically, Casgevy prevented severe vaso-occlusive crises in 93.5% of treated sickle-cell patients, proving that accurate template design translates into therapeutic success. Investor sentiment mirrors demand; Constructive Bio attracted USD 58 million in Series A funding as synthetic genomics promises to ease global peptide shortages. These developments shorten development timelines and intensify competition for trustworthy synthesis partners.
Government Genomics-Funding Initiatives
The NHGRI has allocated USD 1.5 million annually through 2029 to accelerate platform technologies, including enzymatic oligo production. India’s BioE3 framework backs precision biotherapeutics and biomanufacturing with fiscal incentives and regulatory streamlining. The European Union’s SYNBEE project offers grants that help startups integrate AI with DNA design. Japan targets a biotechnology market worth 15 trillion yen by 2030 and emphasizes induced pluripotent stem-cell research that relies on long synthetic genes. Public funding reduces commercial risk, expands installed synthesis capacity, and lifts regional adoption rates.
Rapid Drop in DNA-Synthesis Cost & Turnaround
Enzymatic platforms now allow same-day oligo printing without hazardous solvents, narrowing the gap between sequencing and synthesis speeds. Ribbon Biolabs recently demonstrated 20 kb fragments featuring 0.33% error rates, which expands addressable gene length beyond what chemical methods routinely manage. The University of California Irvine’s proof-of-concept 10-92 TNA polymerase shows academia’s role in boosting both yield and fidelity. WuXi STA has scaled to 27 oligonucleotide lines, underscoring global moves to industrial volumes. Cost declines encourage wider experimentation, sustaining double-digit growth for the gene synthesis market.
Restraints Impact Analysis
Restraint | ( ~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
---|---|---|---|
Scarcity of skilled synthetic-biology workforce | -2.1% | Global, acute in Europe & emerging markets | Long term (≥ 4 years) |
High capital cost for large-scale synthesis capacity | -1.8% | Global, particularly challenging for new entrants | Medium term (2-4 years) |
IP-ownership uncertainty for de-novo constructs | -1.3% | Global, complex in multi-jurisdictional operations | Long term (≥ 4 years) |
Biosecurity & dual-use regulatory scrutiny | -1.6% | Global, stringent in North America & Europe | Medium term (2-4 years) |
Source: Mordor Intelligence
Scarcity of Skilled Synthetic-Biology Workforce
Synthetic biology blends molecular biology, engineering, and computation, yet most academic curricula still emphasize traditional wet-lab skills. NHGRI earmarked USD 5.25 million to boost workforce diversity, signalling institutional recognition of the shortage. European biotechnology contributes EUR 31 billion to GDP but already suffers talent bottlenecks that curtail start-up scaling. Japan’s venture funding remains low relative to the United States, partly because of limited entrepreneurial depth. Continuous retraining is essential because enzymatic platforms require new skill sets compared with phosphorus-based chemistry. Without enough qualified staff, production lines risk under-utilization, slowing revenue accrual for the gene synthesis market.
High Capital Cost for Large-Scale Synthesis Capacity
Solid-phase synthesis equipment, purification columns, and waste-handling systems demand multimillion-dollar investments before a single order ships. Molecular Assemblies raised USD 25.8 million solely to commercialize fully enzymatic flow-platforms. Thermo Fisher committed USD 2 billion to expand United States manufacturing and R&D through 2028, revealing the size of budgets required to stay competitive. FDA’s Advanced Manufacturing Technologies program provides regulatory support yet still requires extensive validation, adding expense and time. Smaller entrants that cannot amortize equipment quickly may exit or become acquisition targets, tempering fresh innovation within the gene synthesis market.
Segment Analysis
By Synthesis Method: Enzymatic Platforms Challenge Chemical Dominance
Chemical oligonucleotide synthesis retained 55.45% gene synthesis market share in 2024 thanks to decades of process optimization and reliable supply chains. Solid-phase phosphoramidite reactions remain standard for short strands, and microchip-based approaches improve batch throughput. Yet the gene synthesis market is pivoting as assembly technologies post a 17.21% CAGR through 2030, propelled by the need for longer constructs in CRISPR and viral vectors.
Enzymatic platforms such as DNA Script’s SYNTAX produce up to 96 oligos within hours, offering laboratories instant access without toxic solvents. Molecular Assemblies’ fully enzymatic flow technology further reduces error rates while extending read length, positioning it to steal share from incumbent methods. Hybrid strategies that combine chemical speed for short primers with enzymatic assembly for long genes are emerging, ensuring the gene synthesis market continues to diversify rather than converge on a single technique.
Note: Segment shares of all individual segments available upon report purchase
By Service Type: Viral Gene Synthesis Accelerates Vaccine Development
Antibody DNA synthesis contributed 48.28% of the gene synthesis market size in 2024 because of rising antibody-drug conjugate pipelines and CAR-T cell interest. Viral gene synthesis is set for a 17.34% CAGR as mRNA platforms and viral vectors dominate vaccine and gene-therapy arenas.
CEPI funding of automated template production confirmed strategic urgency to shorten vaccine R&D cycles. Johnson & Johnson’s collaboration with GenScript on approved CAR-T therapies exemplifies how proprietary antibody sequences generate recurring orders. Service providers capable of bundling sequence design, enzymatic synthesis, and AI-based optimization stand to capture premium contracts, expanding overall revenue for the gene synthesis market.
By Application: Diagnosis Adoption Broadens Commercial Base
Gene and cell therapy represented 52.21% of demand in 2024, strengthened by the FDA’s accelerating approval cadence for one-time genetic treatments. Disease-diagnosis applications will expand at a 17.37% CAGR as hospitals embed genomic assays into routine care.
Rapid neonatal genome sequencing now proves clinically necessary in 60% of level IV NICU cases, creating daily demand for custom probes and controls. AI-designed regulatory sequences developed by the Centre for Genomic Regulation enable ultra-selective expression, opening new markets for design-plus-build services. Together, these forces sustain diversity in application mix, keeping the gene synthesis market resilient to therapeutic-pipeline volatility.

Note: Segment shares of all individual segments available upon report purchase
By End User: Outsourcing Propels CRO and CDMO Growth
Biopharmaceutical firms still drove 46.23% of revenue in 2024 by ordering large volumes for internal programs. However, CROs and CDMOs are forecast to record the swiftest 17.43% CAGR as sponsors externalize synthesis to focus on clinical strategy.
GenScript’s USD 224 million raise earmarked for CDMO expansion signals supplier confidence in the outsourcing wave. Twist Bioscience posted USD 92.8 million revenue for Q2 2025 on the back of diversified customer pools in both synthetic biology and next-generation sequencing. Academic consortia funded by NHGRI further diversify revenue streams, ensuring broad demand stability for the gene synthesis market.
Geography Analysis
North America commanded 42.31% of the gene synthesis market size in 2024 because of strong venture capital flows, mature biopharmaceutical clusters, and supportive regulation. The NHGRI’s USD 1.5 million annual commitment to platform technologies fosters public-private partnerships, while the FDA’s coordinated gene-therapy review pathway removes regulatory uncertainty. Private firms mirror policy confidence; Thermo Fisher is spending USD 2 billion on domestic capacity expansions through 2028.
Asia-Pacific is projected to log a 17.61% CAGR through 2030 and is the fastest-growing region in the gene synthesis market. China classifies biotechnology as a strategic pillar and channels generous subsidies into synthetic genetics ventures. India’s BioE3 policy prioritizes precision biotherapeutics and positions local biofoundries to serve global clients. Japan plans to double private drug-discovery investment by 2028, with induced pluripotent stem-cell projects demanding long synthetic sequences. South Korea’s cell-therapy initiatives further reinforce regional momentum.
Europe remains a steady growth contributor as coordinated policy frameworks such as the EU Bioeconomy Strategy back industrial biotechnology. SYNBEE grants help startups combine AI and DNA design, while the continent’s pharmaceutical giants deliver consistent order volumes. Middle East and Africa along with South America are early in adoption cycles, yet rising healthcare spending and agricultural biotech needs are widening the addressable base for the gene synthesis market.

Competitive Landscape
Competitive intensity is moderate. Market leaders—Twist Bioscience, GenScript Biotech, Thermo Fisher Scientific, and Integrated DNA Technologies—compete on accuracy, turnaround, and platform breadth rather than price. Twist reported 49.6% gross margin during Q2 2025, demonstrating healthy economics once scale is achieved. GenScript’s funding round earmarked for CDMO expansion shows incumbents reinvesting to hold share. Patent filings such as CRISPR Therapeutics’ genomic-editing compositions (11,332,760) protect technological edges and create licensing revenue streams.
Disruptors pursue enzymatic, microfluidic, and automation-rich solutions. DNA Script secured USD 165 million in Series C for its SYNTAX printer and now partners with pharmaceutical firms on same-day oligo supply. Constructive Bio’s USD 58 million raise focuses on rewriting genetic codes to synthesize non-canonical amino acids, challenging current chemical capacity limits. Ribbon Biolabs targets long-fragment niches, while Molecular Assemblies builds proprietary enzymes that extend read length and purity.
Strategic acquisitions accelerate capability stacking. Johnson & Johnson bought Ambrx for USD 2 billion to add antibody-drug conjugate know-how, reflecting big-pharma appetite for upstream genetics. Maravai LifeSciences intends to acquire Officinae Bio’s DNA and RNA assets to broaden AI-enabled mRNA prototyping. Such moves consolidate expertise and raise entry barriers, yet they also validate long-term value within the gene synthesis market.
Gene Synthesis Industry Leaders
-
Merck KGaA
-
Eurofins Genomics
-
Thermo Fisher Scientific
-
GenScript
-
Azenta Life Sciences (Genewiz)
- *Disclaimer: Major Players sorted in no particular order

Recent Industry Developments
- May 2025: Ansa Biotechnologies launched a 50 kb DNA-synthesis early-access program, promising complex sequences within four weeks.
- March 2025: Telesis Bio secured up to USD 21 million to accelerate Gibson SOLA enzymatic DNA-synthesis adoption, enabling on-site production while safeguarding intellectual property.
- February 2025: CEPI awarded DNA Script USD 4.7 million to speed automated DNA template production for mRNA vaccines, supporting the 100 Days Mission.
- September 2024: Constructive Bio closed a USD 58 million Series A with Nobel Laureate Sir Gregory Winter joining the board to advance custom-genome engineering.
Global Gene Synthesis Market Report Scope
As per the scope of the report, gene synthesis refers to the in vitro, base-by-base synthesis of double-stranded DNA molecules. Unlike DNA replication, which occurs in-vivo or by polymerase chain reaction (PCR), gene synthesis does not require a template strand for its initiation. The Gene Synthesis Market is Segmented by Method (Oligonucleotide Synthesis and Gene Assembly), End User (Academic and Research Institute, Biopharmaceutical Companies, And Contract Research Organizations), And Geography (North America, Europe, Asia-Pacific, Middle East and Africa, And South America). The Report Offers the Value (in USD Million) For the Above Segments.
By Synthesis Method | Chemical Oligonucleotide Synthesis | Solid-Phase Phosphoramidite | |
Microchip-based Oligonucleotide Synthesis | |||
Gene Assembly | PCR-mediated | ||
Ligation-mediated | |||
By Service Type | Antibody DNA Synthesis | ||
Viral Gene Synthesis | |||
Others | |||
By Application | Gene and Cell Therapy Developments | ||
Vaccine Development | |||
Disease Diagnosis | |||
Others | |||
By End User | Biopharmaceutical Companies | ||
Academic & Government Institutes | |||
CROs and CDMOs | |||
Others | |||
By Geography | North America | United States | |
Canada | |||
Mexico | |||
Europe | Germany | ||
United Kingdom | |||
France | |||
Italy | |||
Spain | |||
Rest of Europe | |||
Asia-Pacific | China | ||
Japan | |||
India | |||
South Korea | |||
Australia | |||
Rest of Asia-Pacific | |||
Middle East and Africa | GCC | ||
South Africa | |||
Rest of Middle East and Africa | |||
South America | Brazil | ||
Argentina | |||
Rest of South America |
Chemical Oligonucleotide Synthesis | Solid-Phase Phosphoramidite |
Microchip-based Oligonucleotide Synthesis | |
Gene Assembly | PCR-mediated |
Ligation-mediated |
Antibody DNA Synthesis |
Viral Gene Synthesis |
Others |
Gene and Cell Therapy Developments |
Vaccine Development |
Disease Diagnosis |
Others |
Biopharmaceutical Companies |
Academic & Government Institutes |
CROs and CDMOs |
Others |
North America | United States |
Canada | |
Mexico | |
Europe | Germany |
United Kingdom | |
France | |
Italy | |
Spain | |
Rest of Europe | |
Asia-Pacific | China |
Japan | |
India | |
South Korea | |
Australia | |
Rest of Asia-Pacific | |
Middle East and Africa | GCC |
South Africa | |
Rest of Middle East and Africa | |
South America | Brazil |
Argentina | |
Rest of South America |
Key Questions Answered in the Report
What is the current size of the gene synthesis market?
The gene synthesis market size is USD 2.45 billion in 2025, with a forecast value of USD 5.29 billion by 2030 at a 16.64% CAGR.
Which region leads the gene synthesis market?
North America leads with 42.31% of 2024 revenue, buoyed by strong biopharma demand, generous federal funding, and a clear regulatory pathway.
Which synthesis method is growing the fastest?
Gene assembly and other next-generation methods are projected to grow at a 17.21% CAGR, outpacing traditional chemical approaches thanks to longer read lengths and lower error rates.
Why are CROs and CDMOs gaining share in gene synthesis?
Pharmaceutical firms increasingly outsource synthesis to specialized providers, driving a projected 17.43% CAGR for CRO and CDMO revenue over the forecast period.
What major regulatory trends affect market growth?
The FDA’s doubling of annual gene-therapy approvals and the U.S. Executive Order on biotechnology screening both increase demand while clarifying compliance expectations.
How are enzymatic platforms influencing cost and speed?
Enzymatic DNA printers such as SYNTAX can produce purified oligos in hours, cutting turnaround time and reducing hazardous waste, which is accelerating adoption among research and manufacturing users.
Page last updated on: June 20, 2025